Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed
by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment
of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with
bevacizumab. Bevacizumab is an antibody which works differently from the way other
chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by
decreasing the blood supply to the tumors by binding to a substance found on cancer cells
called VEGF (vascular endothelial growth factor). Bevacizumab is approved by the FDA for the
treatment of colorectal cancer and lung cancer. However, it is not approved for the treatment
of breast cancer. Another goal of this research is to determine whether we can develop a way
to identify tumors that will respond well to this study treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Ian E. Krop, MD, PhD
Collaborators:
Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital New Hampshire Oncology-Hematology PA